Search

Your search keyword '"Lee, Yong Joon"' showing total 398 results
Start Over Author "Lee, Yong Joon"
398 results on '"Lee, Yong Joon"'

2. Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial

Author

Hong, Sung-Jin, Lee, Yong-Joon, Kang, Woong Chol, Hong, Bum-Kee, Lee, Jong-Young, Lee, Jin-Bae, Yang, Tae-Hyun, Yoon, Junghan, Lee, Seung-Jun, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2024
Full Text
View/download PDF

3. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea

Author

Hong, Sung-Jin, Lee, Seung-Jun, Lee, Sang-Hyup, Lee, Jong-Young, Cho, Deok-Kyu, Kim, Jin Won, Kim, Sang Min, Hur, Seung-Ho, Heo, Jung Ho, Jang, Ji-Yong, Koh, Jin Sin, Won, Hoyoun, Lee, Jun-Won, Hong, Soon Jun, Kim, Dong-Kie, Choe, Jeong Cheon, Lee, Jin Bae, Kim, Soo-Joong, Yang, Tae-Hyun, Lee, Jung-Hee, Hong, Young Joon, Ahn, Jong-Hwa, Lee, Yong-Joon, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Byeong-Keuk

Published
2024
Full Text
View/download PDF

6. Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial

Author

Lee, Sang-Hyup, Lee, Seung-Jun, Heo, Jung Ho, Ahn, Sung Gyun, Doh, Joon-Hyoung, Shin, Sanghoon, Shim, Jaemin, Her, Ae-Young, Kim, Byung Gyu, Lim, Sang Wook, Kwon, Taek-Geun, Lee, Kyoung-Hoon, Kim, Daehoon, Lee, Yong-Joon, Yu, Hee Tae, Kim, Tae-Hoon, Shin, Dong-Ho, Pak, Hui-Nam, and Kim, Jung-Sun

Published
2024
Full Text
View/download PDF

9. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial

Author

Hong, Sung-Jin, Lee, Seung-Jun, Suh, Yongsung, Yun, Kyeong Ho, Kang, Tae Soo, Shin, Sanghoon, Kwon, Sung Woo, Lee, Jun-Won, Cho, Deok-Kyu, Park, Jong-Kwan, Bae, Jang-Whan, Kang, Woong Cheol, Kim, Seunghwan, Lee, Yong-Joon, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2024
Full Text
View/download PDF

12. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Author

Lee, Bom, Hong, Sung-Jin, Rha, Seung-Woon, Heo, Jung Ho, Hur, Seung-Ho, Choi, Hyun Hee, Kim, Kyung-Jin, Kim, Ju Han, Kim, Hyun Kuk, Kim, Ung, Choi, Yu Jeong, Lee, Yong-Joon, Lee, Seung-Jun, Ahn, Chul-Min, Ko, Young-Guk, Kim, Byeong-Keuk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Jung-Sun

Published
2023
Full Text
View/download PDF

14. Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial

Author

Hong, Myeong-Ki, Choi, Donghoon, Ko, Young-Guk, Kim, Byeong-Keuk, Kim, Jung-Sun, Ahn, Chul-Min, Hong, Sung-Jin, Lee, Seung-Jun, Lee, Yong-Joon, Hong, Bum-Kee, Kwon, Hyuck Moon, Kim, Jong-Youn, Min, Pil Ki, Yoon, Young Won, Lee, Byoung Kwon, Rim, Se-Joong, Choi, Eui-Young, CholKang, Woong, Oh, Pyung Chun, Lee, Jong-Young, Lee, Jin-Bae, Kim, Kee Sik, Choi, Ji Yong, Ryu, Jae Kean, Hong, Seung Pyo, Kim, Chang Yeon, Yang, Tae-Hyun, Cho, Hyung-Jin, Yoon, Junghan, Ahn, Min-Soo, Ahn, Sung Gyun, Lee, Jun-Won, Son, Jung-Woo, Jang, Yangsoo, Yoon, Hyuck-Jun, Lee, Cheol Hyun, Hwang, Jongmin, Cho, Yun-Kyeong, Hur, Seung-Ho, Han, Seongwook, Nam, Chang-Wook, Kim, Hyoungseop, Park, Hyoung-Seob, Kim, In-Cheol, Cho, Yun-Hyeong, Jeong, Hyeon-Ju, Kim, Jin-Ho, Lim, Chewan, Suh, Yongsung, Hwang, Eui Seok, Lee, Ji Hyun, Lee, Sung Yun, Kwon, Sung Uk, Kim, Song-Yi, Park, Keun-Ho, Ki, Hyun Kuk, and Kang, Woong Chol

Published
2023
Full Text
View/download PDF

15. Perioperative Antiplatelet Strategy in Patients Undergoing Noncardiac Surgery Within One Year After Percutaneous Coronary Intervention

Author

Lee, Sang-Hyup, Kim, Choongki, Shin, Sanghoon, Kim, Hyeongsoo, Park, Jong-Kwan, Oh, Seung-Jin, Ahn, Sung Gyun, Cho, Sungsoo, Lee, Oh-Hyun, Moon, Jae Youn, Won, Hoyoun, Suh, Yongsung, Cho, Yun-Hyeong, Cho, Jung Rae, Lee, Byoung-Kwon, Lee, Yong-Joon, Lee, Seung-Jun, Hong, Sung-Jin, Shin, Dong-Ho, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Jung-Sun

Published
2023
Full Text
View/download PDF

17. 4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

Author

Kim, Hyung‐Don, Park, Seongyeol, Jeong, Seongju, Lee, Yong Joon, Lee, Hoyoung, Kim, Chang Gon, Kim, Kyung Hwan, Hong, Seung‐Mo, Lee, Jung‐Yun, Kim, Sunghoon, Kim, Hong Kwan, Min, Byung Soh, Chang, Jong Hee, Ju, Young Seok, Shin, Eui‐Cheol, Song, Gi‐Won, Hwang, Shin, and Park, Su‐Hyung

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Rare Diseases, Digestive Diseases, Cancer, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Aged, CD8-Positive T-Lymphocytes, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating, Male, Middle Aged, Programmed Cell Death 1 Receptor, Tumor Necrosis Factor Receptor Superfamily, Member 9, Medical Biochemistry and Metabolomics, Clinical Sciences, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsTargeting costimulatory receptors with agonistic antibodies is a promising cancer immunotherapy option. We aimed to investigate costimulatory receptor expression, particularly 4-1BB (CD137 or tumor necrosis factor receptor superfamily member 9), on tumor-infiltrating CD8+ T cells (CD8+ tumor-infiltrating lymphocytes [TILs]) and its association with distinct T-cell activation features among exhausted CD8+ TILs in hepatocellular carcinoma (HCC).Approach and resultsTumor tissues, adjacent nontumor tissues, and peripheral blood were collected from HCC patients undergoing surgical resection (n = 79). Lymphocytes were isolated and used for multicolor flow cytometry, RNA-sequencing, and in vitro functional restoration assays. Among the examined costimulatory receptors, 4-1BB was most prominently expressed on CD8+ TILs. 4-1BB expression was almost exclusively detected on CD8+ T cells in the tumor-especially on programmed death 1 (PD-1)high cells and not PD-1int and PD-1neg cells. Compared to PD-1int and 4-1BBneg PD-1high CD8+ TILs, 4-1BBpos PD-1high CD8+ TILs exhibited higher levels of tumor reactivity and T-cell activation markers and significant enrichment for T-cell activation gene signatures. Per-patient analysis revealed positive correlations between percentages of 4-1BBpos cells among CD8+ TILs and levels of parameters of tumor reactivity and T-cell activation. Among highly exhausted PD-1high CD8+ TILs, 4-1BBpos cells harbored higher proportions of cells with proliferative and reinvigoration potential. Our 4-1BB-related gene signature predicted survival outcomes of HCC patients in the The Cancer Genome Atlas cohort. 4-1BB agonistic antibodies enhanced the function of CD8+ TILs and further enhanced the anti-PD-1-mediated reinvigoration of CD8+ TILs, especially in cases showing high levels of T-cell activation.Conclusion4-1BB expression on CD8+ TILs represents a distinct activation state among highly exhausted CD8+ T cells in HCC. 4-1BB costimulation with agonistic antibodies may be a promising strategy for treating HCCs exhibiting prominent T-cell activation.

Published
2020

18. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial

Author

Park, Jong-Il, Lee, Seung-Jun, Lee, Yong-Joon, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Kim, Jung-Sun, Hong, Bum-Kee, Lee, Jung-Hee, Kim, Ung, Cho, Yun-Hyeong, Shin, Won-Yong, Lim Jang, Sang-Wook Yangsoo, Kang, Woong-Chol, Park Jung, Yongwhi Young Hoon, Lee, Sung-Yoon, Kim, Kyoung Jin, Hong, Soon-Jun, Yun, Kyeong Ho, Heo, Jung Ho, Rha, Seung-Woon, Choi, Woong Gil, Lee, Wang Soo Lee, Jung, Jinok, Choi, Sunghoon, Cho, Youn Haeng, Park, Woo Jung, Youn, Changhwan, Hur, Seung Ho, Choi, Hyun Hee, Kim, Ju Han, Kim, Hyun Kuk, Choi, Yu-Jung, Lim, Sang-Wook, Park, Yongwhi, and Jang, Yangsoo

Published
2023
Full Text
View/download PDF

21. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

Author

Chuah, Samuel, Lee, Joycelyn, Song, Yuan, Kim, Hyung-Don, Wasser, Martin, Kaya, Neslihan A., Bang, Kyunghye, Lee, Yong Joon, Jeon, Seung Hyuck, Suthen, Sheena, A’Azman, Shamirah, Gien, Gerald, Lim, Chun Jye, Chua, Camillus, Hazirah, Sharifah Nur, Lee, Hong Kai, Lim, Jia Qi, Lim, Tony K.H., Yeong, Joe, Chen, Jinmiao, Shin, Eui-Cheol, Albani, Salvatore, Zhai, Weiwei, Yoo, Changhoon, Liu, Haiyan, Choo, Su Pin, Tai, David, and Chew, Valerie

Published
2022
Full Text
View/download PDF

22. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Author

Kim, Byeong-Keuk, Hong, Sung-Jin, Lee, Yong-Joon, Hong, Soon Jun, Yun, Kyeong Ho, Hong, Bum-Kee, Heo, Jung Ho, Rha, Seung-Woon, Cho, Yun-Hyeong, Lee, Seung-Jun, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2022
Full Text
View/download PDF

27. Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.

Author

Lee, Yong-Joon, Shin, Sanghoon, Kwon, Sung Woo, Suh, Yongsung, Yun, Kyeong Ho, Kang, Tae Soo, Lee, Jun-Won, Cho, Deok-Kyu, Park, Jong-Kwan, Bae, Jang-Whan, Kang, Woong Cheol, Kim, Seunghwan, Lee, Seung-Jun, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, and Jang, Yangsoo

Subjects
ACUTE coronary syndrome, PLATELET aggregation inhibitors, MYOCARDIAL infarction, CLINICAL trials, TICAGRELOR
Abstract

Background and Aims In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy and safety of ticagrelor monotherapy after short-term DAPT, especially in patients with ACS. Methods Electronic databases were searched from inception to 11 November 2023, and for the primary analysis, individual patient data were pooled from the relevant randomized clinical trials comparing ticagrelor monotherapy after short-term (≤3 months) DAPT with ticagrelor-based 12-month DAPT, exclusively in ACS patients undergoing DES implantation. The co-primary endpoints were ischaemic endpoint (composite of all-cause death, myocardial infarction, or stroke) and bleeding endpoint [Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding] at 1 year. Results Individual patient data from two randomized clinical trials including 5906 ACS patients were analysed. At 1 year, the primary ischaemic endpoint did not differ between the ticagrelor monotherapy and ticagrelor-based DAPT groups [1.9% vs. 2.5%; adjusted hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.56–1.13; P =.194]. The incidence of the primary bleeding endpoint was lower in the ticagrelor monotherapy group (2.4% vs. 4.5%; adjusted HR 0.54; 95% CI 0.40–0.72; P <.001). The results were consistent in a secondary aggregate data meta-analysis including the ACS subgroup of additional randomized clinical trials which enrolled patients with ACS as well as chronic coronary syndrome. Conclusions In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding without a concomitant increase in ischaemic events compared with ticagrelor-based 12-month DAPT. Study registration PROSPERO (ID: CRD42023476470). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial.

Author

Ko, Young-Guk, Lee, Seung-Jun, Ahn, Chul-Min, Lee, Sang-Hyup, Lee, Yong-Joon, Kim, Byeong-Keuk, Hong, Myeong-Ki, Jang, Yangsoo, Kim, Tae-Hoon, Park, Ha-Wook, Jang, Ji Yong, Lee, Jae-Hwan, Park, Jae-Hyeong, Kim, Su Hong, Im, Eui, Park, Sang-ho, Choi, Donghoon, and investigators, IVUS-DCB

Subjects
INTRAVASCULAR ultrasonography, TRANSLUMINAL angioplasty, ENDOVASCULAR surgery, PERIPHERAL vascular diseases, ARTERIAL diseases
Abstract

Background and Aims Drug-coated balloons (DCBs) have demonstrated favourable outcomes following endovascular therapy for femoropopliteal artery (FPA) disease. However, uncertainty remains whether the use of intravascular ultrasound (IVUS) can improve the outcomes of DCBs. Methods This prospective, multicentre, randomized trial, conducted at seven centres in South Korea, compared the outcomes of IVUS-guided vs. angiography-guided angioplasty for treating FPA disease with DCBs. Patients were assigned to receive IVUS-guided (n = 119) or angiography-guided (n = 118) angioplasty using DCBs. The primary endpoint was 12-month primary patency. Results Between May 2016 and August 2022, 237 patients were enrolled and 204 (86.0%) completed the trial (median follow-up; 363 days). The IVUS guidance group showed significantly higher primary patency [83.8% vs. 70.1%; cumulative difference 19.6% (95% confidence interval 6.8 to 32.3); P =.01] and increased freedom from clinically driven target lesion revascularization [92.4% vs. 83.0%; difference 11.6% (95% confidence interval 3.1 to 20.1); P =.02], sustained clinical improvement (89.1% vs. 76.3%, P =.01), and haemodynamic improvement (82.4% vs. 66.9%, P =.01) at 12 months compared with the angiography guidance group. The IVUS group utilized larger balloon diameters and pressures for pre-dilation, more frequent post-dilation, and higher pressures for post-dilation, resulting in a greater post-procedural minimum lumen diameter (3.90 ± 0.59 vs. 3.71 ± 0.73 mm, P =.03). Conclusions Intravascular ultrasound guidance significantly improved the outcomes of DCBs for FPA disease in terms of primary patency, freedom from clinically driven target lesion revascularization, and sustained clinical and haemodynamic improvement at 12 months. These benefits may be attributed to IVUS-guided optimization of the lesion before and after DCB treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy

Author

Jeon, Seung Hyuck, primary, Kang, Minyong, primary, Jeon, Minwoo, primary, Chung, Youseung, primary, Kim, A Reum, primary, Lee, Yong Joon, primary, Kim, Eui-Soon, primary, Nam, Heejin, primary, Park, Junsik, primary, Lee, Jung-Yun, primary, Shin, Eui-Cheol, primary, Seo, Seong Il, primary, and Park, Su-Hyung, primary

Published
2024
Full Text
View/download PDF

33. Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy

Author

Jeon, Seung Hyuck, primary, Kang, Minyong, primary, Jeon, Minwoo, primary, Chung, Youseung, primary, Kim, A Reum, primary, Lee, Yong Joon, primary, Kim, Eui-Soon, primary, Nam, Heejin, primary, Park, Junsik, primary, Lee, Jung-Yun, primary, Shin, Eui-Cheol, primary, Seo, Seong Il, primary, and Park, Su-Hyung, primary

Published
2024
Full Text
View/download PDF

35. Continuous Renal Replacement Therapy and Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock: A Multicenter Observational Study: Results from the RESCUE Registry

Author

Lim, Chewan, primary, Chung, Young Hak, additional, Ahn, Chul-Min, additional, Cho, Sungsoo, additional, Yang, Jeong Hoon, additional, Kang, Tae Soo, additional, Lee, Sang-Hyup, additional, Lee, Yong Joon, additional, Lee, Seung Jun, additional, Hong, Sung Jin, additional, Kim, Jung Sun, additional, Kim, Byeong Keuk, additional, Ko, Young Guk, additional, Choi, Donghoon, additional, Gwon, Hyeon Cheol, additional, Hong, Myeong Ki, additional, and Jang, Yangsoo, additional

Published
2024
Full Text
View/download PDF

36. Appropriate Number of Adjuvant Chemotherapy Cycles for Patients with Stage 2 or 3 Gastric Cancer After Curative Gastrectomy: A Multicenter Cohort Study

Author

Jeong, Sang-Ho, Yoo, Moon-Won, Son, Young-Gil, Oh, Sung Jin, Kim, Jong-Han, Kim, Hyoung-Il, Park, Joong-Min, Hur, Hoon, Jee, Ye Seob, Hwang, Sun-Hwi, Jin, Sung-Ho, Lee, Sang Eok, Lee, Yong-Joon, Seo, Kyung Won, Park, Sungsoo, Lee, Chang Min, Kim, Chang Hyun, Jeong, In Ho, Lee, Han Hong, Choi, Sung Il, Lee, Sang-Il, Kim, Chan Young, Chae, Hyundong, Son, Myoung-Won, Pak, Kyung Ho, Kim, Sungsoo, Lee, Moon-Soo, and Min, Jae-Seok

Published
2021
Full Text
View/download PDF

38. Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial.

Author

Lee, Seung-Jun, Lee, Jin-Bae, Yang, Tae-Hyun, Kang, Woong Chol, Lee, Jong-Young, Lee, Yong-Joon, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Hong, Bum-Kee, Choi, Donghoon, Yoon, Junghan, Jang, Yangsoo, Hong, Myeong-Ki, and investigators, for the LODESTAR

Subjects
MYOCARDIAL infarction risk factors, MORTALITY risk factors, PATIENT safety, RESEARCH funding, SECONDARY analysis, TREATMENT effectiveness, DESCRIPTIVE statistics, LDL cholesterol, AGE distribution, MYOCARDIAL revascularization, STATINS (Cardiovascular agents), DRUG efficacy, CORONARY artery disease, CONFIDENCE intervals, STROKE, EVALUATION, DISEASE risk factors, OLD age
Abstract

Background The optimal statin treatment strategy that is balanced for both efficacy and safety has not been clearly determined in older adults with coronary artery disease (CAD). Methods In the post hoc analysis of the LODESTAR (low-density lipoprotein cholesterol-targeting statin therapy versus intensity-based statin therapy in patients with coronary artery disease) trial, the impact between a treat-to-target strategy versus a high-intensity statin therapy strategy was compared in older adults (aged 75 years or older). The goal of treat-to-target low-density lipoprotein cholesterol (LDL-C) level was 50–70 mg/dl. The primary endpoint comprised the three-year composite of all-cause death, myocardial infarction, stroke or coronary revascularisation. Results Among 4,400 patients with CAD enrolled in the LODESTAR trial, 822 (18.7%) were aged 75 years or older. Poor clinical outcomes and risk factors for atherosclerosis were more frequently observed in older adults than in younger population (<75 years old). Among these older adults with CAD, the prescription rate of high-intensity statin was significantly lower in the treat-to-target strategy group throughout the study period (P  < 0.001). The mean LDL-C level for three years was 65 ± 16 mg/dl in the treat-to-target strategy group and 64 ± 18 mg/dl in the high-intensity statin group (P  = 0.34). The incidence of primary endpoint occurrence was 10.9% in the treat-to-target strategy group and 12.0% in the high-intensity statin group (hazard ratio 0.92, 95% confidence interval 0.61–1.38, P  = 0.69). Conclusions High-intensity statin therapy is theoretically more necessary in older adults because of worse clinical outcomes and greater number of risk factors for atherosclerosis. However, the primary endpoint occurrence with a treat-to-target strategy with an LDL-C goal of 50–70 mg/dl was comparable to that of high-intensity statin therapy and reduced utilisation of a high-intensity statin. Taking efficacy as well as safety into account, adopting a tailored approach may be considered for this high-risk population. Trial Registration ClinicalTrials.gov , NCT02579499. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Comparison of Intracardiac Echocardiography Versus Transesophageal Echocardiography for Guidance During Transcatheter Aortic Valve Replacement

Author

Lee, Sang-Hyup, primary, Oh, Seunguk, additional, Ko, Young-Guk, additional, Lee, Yong-Joon, additional, Lee, Seung-Jun, additional, Hong, Sung-Jin, additional, Ahn, Chul-Min, additional, Kim, Jung-Sun, additional, Kim, Byeong-Keuk, additional, Ko, Kyu-Yong, additional, Cho, Iksung, additional, Shim, Chi Young, additional, Hong, Geu-Ru, additional, Choi, Donghoon, additional, and Hong, Myeong-Ki, additional

Published
2024
Full Text
View/download PDF

42. Moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post‐hoc analysis of the RACING trial

Author

Lee, Yong‐Joon, primary, Lee, Sang‐Hyup, additional, You, Seng Chan, additional, Lee, Yong‐ho, additional, Lee, Seung‐Jun, additional, Hong, Sung‐Jin, additional, Ahn, Chul‐Min, additional, Kim, Byeong‐Keuk, additional, Ko, Young‐Guk, additional, Choi, Donghoon, additional, Hong, Myeong‐Ki, additional, Jang, Yangsoo, additional, and Kim, Jung‐Sun, additional

Published
2023
Full Text
View/download PDF

43. Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability

Author

Lee, Seung-Jun, primary, Joo, Jae Hong, additional, Park, Sohee, additional, Kim, Choongki, additional, Choi, Dong-Woo, additional, Lee, Yong-Joon, additional, Hong, Sung-Jin, additional, Ahn, Chul-Min, additional, Kim, Jung-Sun, additional, Kim, Byeong-Keuk, additional, Ko, Young-Guk, additional, Choi, Donghoon, additional, Jang, Yangsoo, additional, Nam, Chung-Mo, additional, and Hong, Myeong-Ki, additional

Published
2023
Full Text
View/download PDF

47. Moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post‐hoc analysis of the RACING trial.

Author

Lee, Yong‐Joon, Lee, Sang‐Hyup, You, Seng Chan, Lee, Yong‐ho, Lee, Seung‐Jun, Hong, Sung‐Jin, Ahn, Chul‐Min, Kim, Byeong‐Keuk, Ko, Young‐Guk, Choi, Donghoon, Hong, Myeong‐Ki, Jang, Yangsoo, and Kim, Jung‐Sun

Subjects
*METABOLIC syndrome, *LDL cholesterol, *CARDIOVASCULAR diseases, *HDL cholesterol, *STATINS (Cardiovascular agents), *SIMVASTATIN, *INTERVAL training, *HIGH-intensity interval training
Abstract

Aim: This study evaluated the safety and efficacy of a moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome (MetS) and atherosclerotic cardiovascular disease. Materials and Methods: In this post‐hoc subgroup analysis of the RACING trial, patients were analysed based on the presence of MetS. MetS was defined as meeting at least three of the five following criteria: (a) elevated waist circumference; (b) elevated triglycerides; (c) reduced high‐density lipoprotein cholesterol; (d) elevated blood pressure; and (e) elevated fasting glucose. The primary outcome was a 3‐year composite of cardiovascular death, major cardiovascular events, or non‐fatal stroke. Results: Of the 3780 patients enrolled in the RACING trial, 1703 (45.1%) had MetS at baseline. The primary outcome rate was 10.1% and 10.3% in patients with MetS receiving ezetimibe combination therapy versus high‐intensity statin monotherapy (hazard ratio = 0.97; 95% confidence interval = 0.72‐1.32; p =.868). Lower rates of intolerance‐related drug discontinuation or dose reduction (3.9% vs. 8.0%; p <.001) and lower low‐density lipoprotein cholesterol levels (57 vs. 65 mg/dl; p <.001) were observed with ezetimibe combination therapy versus high‐intensity statin monotherapy. Furthermore, the rate of new‐onset diabetes was 18.5% and 19.1% in each group (p =.822). There were no significant interactions between MetS and therapy regarding study outcomes in the total population. Conclusions: In patients with MetS and atherosclerotic cardiovascular disease, a moderate‐intensity statin with ezetimibe combination therapy had comparable cardiovascular benefits with those of high‐intensity statin monotherapy. Meanwhile, ezetimibe combination therapy was associated with lower drug intolerance and low‐density lipoprotein cholesterol levels, but there was no apparent between‐group difference in new‐onset diabetes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial

Author

Lee, Yong-Joon, primary, Hong, Sung-Jin, additional, Kang, Woong Chol, additional, Hong, Bum-Kee, additional, Lee, Jong-Young, additional, Lee, Jin-Bae, additional, Cho, Hyung-Jin, additional, Yoon, Junghan, additional, Lee, Seung-Jun, additional, Ahn, Chul-Min, additional, Kim, Jung-Sun, additional, Kim, Byeong-Keuk, additional, Ko, Young-Guk, additional, Choi, Donghoon, additional, Jang, Yangsoo, additional, and Hong, Myeong-Ki, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results